Document is current
Any future updates will be listed below
-
Authors
Lee, Arthur S. https://orcid.org/0000-0002-4513-4630
Ayers, Lauren J. https://orcid.org/0000-0001-9236-7595
Kosicki, Michael
Chan, Wai-Man https://orcid.org/0000-0002-2888-4739
Fozo, Lydia N. https://orcid.org/0000-0003-2601-8287
Pratt, Brandon M.
Collins, Thomas E.
Zhao, Boxun https://orcid.org/0000-0003-2337-5756
Rose, Matthew F.
Sanchis-Juan, Alba
Fu, Jack M. https://orcid.org/0000-0003-4152-5471
Wong, Isaac https://orcid.org/0000-0003-4877-5748
Zhao, Xuefang
Tenney, Alan P.
Lee, Cassia
Laricchia, Kristen M.
Barry, Brenda J.
Bradford, Victoria R.
Jurgens, Julie A.
England, Eleina M.
Lek, Monkol https://orcid.org/0000-0003-1227-6293
MacArthur, Daniel G.
Lee, Eunjung Alice
Talkowski, Michael E. https://orcid.org/0000-0003-2889-0992
Brand, Harrison
Pennacchio, Len A. https://orcid.org/0000-0002-8748-3732
Engle, Elizabeth C. https://orcid.org/0000-0001-8194-7738
- License Information
-
More Information
Article History
Received: 12 December 2023
Accepted: 4 September 2024
First Online: 27 September 2024
Competing interests
: D.G.M. is a paid advisor to GlaxoSmithKline, Insitro, and Overtone Therapeutics, and has received research support from AbbVie, Astellas, Biogen, BioMarin, Eisai, Google, Merck, Microsoft, Pfizer, and Sanofi-Genzyme. M.E.T. has received research support and/or reagents from Microsoft, Illumina Inc., Pacific Biosciences, and Ionis Pharmaceuticals. Otherwise, the authors declare that they have no competing interests as defined by Nature Research, or other interests that might be perceived to influence the interpretation of this article.
